Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
Condition(s):Acute Lymphocytic Leukemia; Acute Myeloid LeukemiaLast Updated:January 14, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Acute Lymphocytic Leukemia; Acute Myeloid LeukemiaLast Updated:January 14, 2022Completed
Condition(s):Relapsed Pediatric ALL; Relapsed Pediatric AML; Refractory Acute Myeloid Leukemia; Refractory Acute Lymphoblastic LeukemiaLast Updated:June 28, 2023Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:June 9, 2021Unknown status
Condition(s):Acute Myeloid LeukemiaLast Updated:November 2, 2018Unknown status
Condition(s):Acute Myeloid Leukemia (AML)Last Updated:April 27, 2018Completed
Condition(s):Unspecified Childhood Solid Tumor, Protocol SpecificLast Updated:April 14, 2020Completed
Condition(s):Untreated Adult Acute Myeloid LeukemiaLast Updated:May 31, 2023Completed
Condition(s):High-risk (Secondary) Acute Myeloid LeukemiaLast Updated:December 28, 2023Not yet recruiting
Condition(s):Leukemia, Myelocytic, AcuteLast Updated:September 15, 2023Completed
Condition(s):Leukemia; Acute Myeloid Leukemia; AMLLast Updated:October 3, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.